
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TBX18 CRISPR Activation Plasmid (h) | sc-401564-ACT | 20 µg | $397.00 |
TBX18 encodes a T-box family transcription factor that directs embryonic patterning and organogenesis by regulating lineage specification and mesenchymal differentiation programs. In human development, TBX18 is prominently associated with urogenital and musculoskeletal morphogenesis and contributes to cardiac conduction system formation through transcriptional control of developmental gene networks. Its activity intersects with signaling processes that shape tissue boundaries and cell fate decisions, including pathways influenced by WNT, BMP, and FGF cues. Dysregulated TBX18 expression or function has been linked to congenital developmental anomalies, making it a useful node for studying transcriptional circuitry underlying organ development and disease-relevant phenotypes.
TBX18 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous TBX18 expression without altering the underlying DNA sequence.
TBX18 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the TBX18 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the TBX18 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous TBX18 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native TBX18 locus and enabling the study of TBX18-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of TBX18 pathway restoration in tumor cells with silenced or reduced TBX18 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.